Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | THRB | P10828 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA1 | P00915 | 5/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77518 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL17327517 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL19735717 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL24584612 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL20524278 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL23330709 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL258821 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL2723648 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL502378 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR | |
| SCHEMBL13396023 | 1.00 | CYP2D6 (0.70) | CYP2D6THRBHSD17B10CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348521-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | ELYSIUM HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11584771-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | BIOSYNTH AG (CH) | 2023-02-21 | — | — | US | disclosed |
| US-20220378816-A1 | 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGONISTIC ACTIVITY | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-12-01 | — | — | US | disclosed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220135610-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | BIOSYNTH AG (CH) | 2022-05-05 | — | — | US | disclosed |
| US-20210292347-A1 | DIHETEROCYCLIC TRIAZINONE NUCLEOSIDE ANALOGS AND THEIR USE FOR MEDICATION | XU LIFENG (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210206793-A1 | (THIO)NICOTINAMIDE RIBOFURANOSIDE SALTS AND COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2021-07-08 | — | — | US | disclosed |
| WO-2021125708-A1 | NICOTINAMIDE RIBOSIDE DERIVATIVE CONJUGATED TO FATTY AMINE | 주식회사 휴메딕스 | 2021-06-24 | — | — | WO | disclosed |
| CN-108299548-B | Application of BS1-CT protein in regulation and control of plant cell wall xylan deacetylation reaction | 中国科学院遗传与发育生物学研究所 | 2020-06-09 | — | — | CN | disclosed |
| US-20200140475-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | ELYSIUM HEALTH, INC. | 2020-05-07 | — | — | US | disclosed |
| WO-2005070911-A1 | TRANSACETALISATION PROCESS | MONASH UNIVERSITY (AU) | 2005-08-04 | — | — | WO | disclosed |
| US-6921753-B2 | Purine derivatives | PFIZER INC (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040229838-A1 | Purine derivatives | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| EP-1296996-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-1220863-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2003-04-23 | — | — | EP | disclosed |
| EP-1296996-A1 | PURINE DERIVATIVES | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020032168-A1 | Purine derivatives | PFIZER INC. | 2002-03-14 | — | — | US | disclosed |
| US-6350735-B1 | Purine derivatives | PFIZER INC | 2002-02-26 | — | — | US | disclosed |
| WO-2002000676-A1 | PURINE DERIVATIVES | PFIZER LIMITED (GB) | 2002-01-03 | — | — | WO | disclosed |
| US-3996205-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348521-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | NAMPT, NADK, NNT | CYP2D6 2669/4885THRB 1741/4885HSD17B10 658/4885 |
| US-20210292347-A1 | DIHETEROCYCLIC TRIAZINONE NUCLEOSIDE ANALOGS AND THEIR USE FOR MEDICATION | NTPCR, ENTPD5, DPYD | CYP2D6 79/4885THRB 2512/4885HSD17B10 420/4885 |
| US-20040229838-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CYP2D6 238/4885THRB 1435/4885HSD17B10 3679/4885 |
| US-20220378816-A1 | 2-BENZYLIDENE HYDRAZINOADENOSINE COMPOUNDS HAVING A2A ADENOSINE RECEPTOR AGONISTIC ACTIVITY | ADORA2A, ADORA1, ADORA3 | CYP2D6 1064/4885THRB 572/4885HSD17B10 2720/4885 |
| US-20220135610-A1 | METHOD OF MAKING NICOTINAMIDE RIBOFURANOSIDE SALTS, NICOTINAMIDE RIBOFURANOSIDE SALTS AS SUCH, AND USES THEREOF | NAMPT, NNT, NADK | CYP2D6 651/4885THRB 4113/4885HSD17B10 653/4885 |
| US-11584771-B2 | Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof | NAMPT, NNT, NADK | CYP2D6 601/4885THRB 4272/4885HSD17B10 689/4885 |
| US-20020032168-A1 | Purine derivatives | ADORA2A, ADORA1, ADORA3 | CYP2D6 238/4885THRB 1435/4885HSD17B10 3679/4885 |
| US-20210206793-A1 | (THIO)NICOTINAMIDE RIBOFURANOSIDE SALTS AND COMPOSITIONS, METHODS OF MAKING, AND USES THEREOF | NAMPT, NAPRT, NNT | CYP2D6 720/4885THRB 1236/4885HSD17B10 838/4885 |
| US-20200140475-A1 | METHODS OF SYNTHESIZING NICOTINAMIDE RIBOSIDE | NAMPT, NADK, NNT | CYP2D6 2669/4885THRB 1741/4885HSD17B10 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.